Find Paid Clinical Trials in Abbott, Texas

Paid Clinical Trials and Focus Groups by Location

All Locations ... United States » ... Texas » ... Abbott

Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder

Conditions: Depression; Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified March 2010
Peripartum Cardiomyopathy

Condition: Pregnant Women With Peripartum Cardiomyopathy
Intervention:
Sponsors: University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified March 2010
Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Condition: Scalp Psoriasis
Intervention: Drug: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
Sponsor: LEO Pharma
Not yet recruiting - verified March 2010
OTO-104 for Meniere's Disease

Condition: Meniere's Disease
Interventions: Drug: OTO-104 (steroid) 3 mg; Drug: Placebo; Drug: OTO-104 (steroid) 12 mg
Sponsor: Otonomy, Inc.
Recruiting - verified March 2010
Investigation of the Ability of the MECC System to Provide Reduced Risk Over the Existing CECC System and Equivalent Risk to Off-Pump CABG Surgery.

Condition: Surgery
Intervention:
Sponsor: Baylor Research Institute
Recruiting - verified March 2010
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

Condition: Renal Impairment
Interventions: Drug: Febuxostat; Drug: Febuxostat; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified March 2010
"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"

Conditions: Acne; Patient Compliance
Intervention: Other: Text message reminders
Sponsors: University of Texas Southwestern Medical Center; University of California, Davis
Recruiting - verified January 2010
Prospective Analysis of Cerebral Perfusion Using Head Ultrasound and Multi-source-detector Near Infrared Spectroscopy (NIRS) Imaging

Condition: Congenital Heart Disease
Intervention:
Sponsors: University of Texas Southwestern Medical Center; The University of Texas at Arlington
Not yet recruiting - verified March 2010
The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 100 mg; Drug: Placebo/sitagliptin 2x50 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
A Study in Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsor: Eli Lilly and Company
Not yet recruiting - verified March 2010
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicines.

Condition: Acute Gout
Interventions: Drug: ACZ885; Drug: Triamcinolone acetonide
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified March 2010
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: NN1250; Drug: insulin glargine; Drug: NN1250; Drug: insulin aspart
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Polyneuropathy
Interventions: Drug: SB-509; Other: Saline
Sponsors: Sangamo Biosciences; Juvenile Diabetes Research Foundation
Recruiting - verified March 2010
Evaluation of FID 114657 in Sjogren's Syndrome Subjects

Condition: Sjogren's Syndrome
Intervention: Drug: FID 114657 (ORB Preserved Ocular Emulsion)
Sponsor: Alcon Research
Recruiting - verified March 2010
FID 114657 (ORB Preserved Ocular Emulsion)

Condition: Meibomian Gland Dysfunction
Intervention: Drug: FID 114657 (ORB Preserved Ocular Emulsion)
Sponsor: Alcon Research
Recruiting - verified March 2010
Lenalidomide and High-Dose Melphalan

Conditions: Myeloma; Stem Cell Transplantation
Interventions: Drug: Lenalidomide; Drug: Melphalan
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Efficacy and Safety of Different Doses of Indacaterol

Condition: Asthma
Interventions: Drug: Indacaterol dose; Drug: Placebo; Drug: Salmeterol
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA); National Institutes of Health (NIH)
Not yet recruiting - verified March 2010
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Condition: Chronic Hepatitis C Virus Infection
Interventions: Drug: telaprevir; Drug: VX-222; Drug: ribavirin; Biological: peginterferon-alfa-2a; Drug: VX-222
Sponsor: Vertex Pharmaceuticals Incorporated
Not yet recruiting - verified March 2010
Performance Evaluation Study for Clearblue Pregnancy Test

Condition: Pregnancy
Intervention:
Sponsor: SPD Development Company Limited
Recruiting - verified February 2010
Ranibizumab for Edema of the mAcula in Diabetes: Protocol 3 With High Dose - the READ 3 Study

Condition: Diabetic Macular Edema
Interventions: Drug: Ranibizumab; Drug: ranibizumab
Sponsors: Johns Hopkins University; Juvenile Diabetes Research Foundation
Recruiting - verified February 2010
Initiation of Colon Cancer Screening in Veterans or "Start Screening Now"

Condition: Colorectal Neoplasms
Interventions: Behavioral: Stepped CRCS Interventions; Behavioral: Control
Sponsors: The University of Texas Health Science Center, Houston; Duke University; Boston University
Recruiting - verified March 2010
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections

Condition: Clostridium Difficile Infection
Interventions: Drug: MIYA-BM Fine Granules (CBM588); Drug: Placebo Fine Granules (without CBM588)
Sponsor: Osel, Inc.
Recruiting - verified February 2010
4968 Post-approval Study

Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
4965 Post-approval Study

Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
nEw3 Post-approval Study

Conditions: Arrhythmia; Bradycardia
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients

Conditions: Pre-Hypertension; Hypertension
Interventions: Drug: Potassium, Magnesium, Citrate; Drug: Potassium Chloride
Sponsor: University of Texas Southwestern Medical Center
Recruiting - verified April 2009
Visual Function After Implantation of AcrySof® Toric Lens

Condition: Cataract
Intervention: Device: AcrySof Toric Intraocular Lens
Sponsor: Alcon Research
Recruiting - verified February 2010
Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections

Condition: Diabetes Mellitus
Interventions: Device: Finesse; Device: Pen/Syringe (Usual injection device)
Sponsors: Calibra Medical, Inc.; Nancy Bohannon, MD, Med. Corp.; Henry Ford Health System; Northwestern University; University of Texas Southwestern Medical Center; Joslin Diabetes Center; International Diabetes Center at Park Nicollet
Recruiting - verified March 2010
Keller Prehospital Ultrasound Study

Conditions: Ultrasonography; Multiple Trauma; Kidney Calculi; Aortic Aneurysm, Abdominal; Pregnancy; Catheterization, Venous
Interventions: Device: EFAST exam; Device: Pelvic Ultrasound; Procedure: Ultrasound Guided Vascular Access; Device: Focused Ultrasound Scan; Device: Cardiac Ultrasound
Sponsor: Keller Fire Rescue
Not yet recruiting - verified February 2010
12-week Efficacy of Indacaterol

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol; Drug: Placebo
Sponsor: Novartis
Recruiting - verified February 2010
Vitespen (HSPPC-96) for Immune Response Assessment Following Treatment of Resectable Renal Cell Carcinoma

Conditions: Kidney Cancer; Renal Cell Carcinoma
Interventions: Biological: Vitespen (HSPPC-96); Biological: Vitespen (HSPPC-96)
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

Conditions: Alzheimer's Disease; Amnestic Mild Cognitive Impairment
Intervention: Drug: Posiphen® tartrate capsules
Sponsor: QR Pharma Inc.
Recruiting - verified February 2010
Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides

Condition: Lymphoma
Intervention: Radiation: TSEBT
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
Rivastigmine as a Treatment for Methamphetamine Dependence

Condition: Methamphetamine Addiction
Interventions: Other: Placebo; Drug: Rivastigmine
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2010
A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: ASP1941; Drug: Metformin; Drug: Placebo
Sponsor: Astellas Pharma Inc
Not yet recruiting - verified February 2010
GDC-0449 and RO4929097 in Treating Women With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Hedgehog antagonist GDC-0449; Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2010
Safety and Efficacy of Moxidex Otic

Condition: Acute Otitis Media
Interventions: Drug: AL-15469A; Drug: AL38905; Drug: AL
Sponsor: Alcon Research
Not yet recruiting - verified February 2010
A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

Conditions: Hyperphosphatemia; End-Stage Renal Disease
Intervention: Drug: ferric citrate
Sponsor: Keryx Biopharmaceuticals
Not yet recruiting - verified February 2010
JCV Antibody Program

Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Elan Pharmaceuticals
Not yet recruiting - verified February 2010
Trial of Percutaneous Endovascular Aneurysm Repair (PEVAR)

Condition: Abdominal Aortic Aneurysm
Interventions: Device: PEVAR (ProGlide closure); Device: SEVAR (IntuiTrak); Device: PEVAR (Prostar XL closure)
Sponsors: Endologix; Abbott Vascular
Not yet recruiting - verified February 2010
Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes

Conditions: CML; Adenovirus Infection
Intervention: Biological: Infusion of CTL lines
Sponsor: Baylor College of Medicine
Not yet recruiting - verified February 2010
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia
Interventions: Drug: A: Azacitidine (Vidaza); Drug: B: Conventional Care Regimen
Sponsor: Celgene Corporation
Not yet recruiting - verified February 2010
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

Conditions: Carcinoma, Non-Small-Cell Lung; Lung Cancer
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Paclitaxel; Drug: Carboplatin; Drug: Bevacizumab
Sponsor: Bayer
Recruiting - verified February 2010
Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Guanfacine Extended Release; Drug: Placebo
Sponsors: The University of Texas Health Science Center at San Antonio; Shire Pharmaceutical Development
Not yet recruiting - verified February 2010
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

Conditions: Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia
Interventions: Drug: bortezomib; Drug: belinostat; Other: laboratory biomarker analysis; Genetic: western blotting; Other: pharmacological study; Other: flow cytometry
Sponsors: Virginia Commonwealth University; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)

Conditions: Epilepsy; Tuberous Sclerosis Complex
Intervention: Drug: Everolimus
Sponsors: Children's Hospital Medical Center, Cincinnati; Novartis
Not yet recruiting - verified February 2010
Compliance and Contamination in Soft Contact Lens Wearers

Condition: Contact Lens Wear
Interventions: Device: OPTI-FREE RepleniSH; Device: Clear Care
Sponsor: Alcon Research
Recruiting - verified February 2010
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified February 2010
Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

Condition: Influenza
Interventions: Drug: Favipiravir; Drug: Favipiravir; Drug: Placebo comparator
Sponsor: Toyama Chemical Co., Ltd.
Recruiting - verified March 2010
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Conditions: Diabetes Mellitus Type 2; Impaired Glucose Tolerance
Interventions: Drug: canakinumab + background diabetes therapy; Drug: placebo + background diabetes therapy
Sponsor: Novartis
Recruiting - verified February 2010
Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK1349572
Sponsors: GlaxoSmithKline; Shionogi
Recruiting - verified March 2010
Bioequivalence Study of 2.5 mg Saxagliptin and 850 mg Glucophage Combination Formulations in Healthy Subjects

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Saxagliptin; Drug: Metformin
Sponsors: Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified February 2010
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Rifampin
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified February 2010
Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Metformin (Diabex); Drug: Metformin (Glucophage™); Drug: Metformin (Diabex); Drug: Metformin (Glucophage™)
Sponsors: Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified February 2010
Bioequivalence Study of 2.5 mg Saxagliptin and 500 mg Glucophage Combination Formulations in Healthy Subjects

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Saxagliptin; Drug: Saxagliptin; Drug: Metformin; Drug: Metformin
Sponsors: Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified February 2010
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)

Condition: Chronic Obstructive Pulmonary Disease
Intervention:
Sponsors: University of Washington; Puget Sound Veterans Administration Health Care System; The University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System
Recruiting - verified February 2010
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Letrozole; Drug: RAD001 (Everolimus)
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); Novartis
Not yet recruiting - verified February 2010
A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

Condition: Head Lice
Interventions: Drug: 0.5% Ivermectin Cream; Drug: Placebo control
Sponsor: Topaz Pharmaceuticals Inc
Not yet recruiting - verified February 2010
Developing a Diabetic Foot Ulcer Protocol

Condition: Diabetic Foot Ulcers
Interventions: Other: type of footwear; Other: collagen dressing with and without silver
Sponsors: The University of Texas Health Science Center, Houston; Harris County Hospital District; Baylor College of Medicine
Not yet recruiting - verified February 2010
Safety and Tolerability of Odanacatib (MK0822)

Condition: Osteoporosis
Interventions: Drug: Odanacatib; Drug: Comparator: Placebo
Sponsor: Merck
Recruiting - verified March 2010
A Postmarket Randomized Study of the Treatment of Superficial Partial-Thickness Burns Using Two Dressings

Condition: Burns
Interventions: Device: AWBAT Wound Dressing; Device: AWBAT™, Biobrane®
Sponsor: Aubrey Inc.
Recruiting - verified February 2010
A 6 Month Study of Once Daily Ciclesonide HFA Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Condition: Perennial Allergic Rhinitis
Intervention: Drug: ciclesonide HFA 160 μg
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Reducing Length of Stay for Veterans Hospitalized With Pneumonia

Condition: Pneumonia
Intervention: Other: reminder
Sponsor: Department of Veterans Affairs
Not yet recruiting - verified February 2010
A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours

Condition: Diabetes
Intervention: Device: Subcutaneous glucose monitoring device
Sponsors: BioTex, Inc.; Eric Orzeck's Practice
Recruiting - verified February 2010
A Study in Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide; Drug: LY2189265; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: ALN-RSV01; Drug: Normal Saline
Sponsor: Alnylam Pharmaceuticals
Recruiting - verified March 2010
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Conditions: Diabetic Neuropathy, Painful; Diabetic Polyneuropathy
Interventions: Drug: Oxycodone controlled release (CR); Drug: Tapentadol extended release (ER)
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Grünenthal GmbH
Recruiting - verified February 2010
Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza

Condition: Influenza
Intervention: Drug: Peramivir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified January 2010
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: KW-2478 and bortezomib
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin UK, Ltd.; Kyowa Hakko Kirin Company, Limited
Not yet recruiting - verified January 2010
The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine

Condition: Cocaine Addiction
Interventions: Drug: Sugar Pill; Drug: Doxazosin
Sponsors: Baylor College of Medicine; National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2010
A Study in Head and Neck Cancer

Condition: Head and Neck Neoplasms
Interventions: Drug: Cetuximab; Drug: Carboplatin; Drug: 5 - Fluorouracil
Sponsor: Eli Lilly and Company
Not yet recruiting - verified February 2010
An Ace Inhibitor as a Treatment for Methamphetamine Dependence.

Condition: Methamphetamine Addiction
Interventions: Drug: Perindopril; Other: Placebo
Sponsors: Baylor College of Medicine; National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2010
NAC as a Potential Treatment for Methamphetamine Dependence

Condition: Methamphetamine Addiction
Interventions: Drug: Placebo (Solution without NAC); Drug: N-acetylcysteine; Drug: N-Acetylcysteine
Sponsors: Baylor College of Medicine; National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified March 2010
Investigation of Cycloserine as a Smoking Cessation Treatment

Condition: Nicotine Addiction
Interventions: Drug: Cycloserine; Drug: Placebo
Sponsors: Baylor College of Medicine; National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2010
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Condition: Myelodysplastic Syndrome
Interventions: Drug: Ezatiostat Hydrochloride; Drug: Lenalidomide (Revlimid®)
Sponsor: Telik
Recruiting - verified February 2010
FOCUS-CI: A Preventive Intervention With Children and Families of the Combat Injured

Conditions: Stress Disorders; Combat Disorders; Traumatic Stress Disorders
Interventions: Behavioral: Standard of Care; Behavioral: FOCUS-CI
Sponsors: Henry M. Jackson Foundation for the Advancement of Military Medicine; U.S. Army Medical Research and Materiel Command
Not yet recruiting - verified March 2010
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

Condition: Glaucoma
Interventions: Drug: AR-12286 0.5% ophthalmic solution; Drug: AR-12286 0.25% Ophthalmic solution; Drug: Latanoprost ophthalmic solution
Sponsor: Aerie Pharmaceuticals
Recruiting - verified March 2010
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: 1 mg PF-04971729; Drug: 5 mg PF-04971729; Drug: 10 mg PF-04971729; Drug: 25 mg PF-04971729; Drug: 100 mg sitagliptin
Sponsor: Pfizer
Recruiting - verified March 2010
Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®

Condition: Osteoarthritis
Interventions: Drug: LT-NS001; Drug: Naprosyn®
Sponsors: Logical Therapeutics; PRA International
Recruiting - verified February 2010
A Phase 1 Study of Brentuximab Vedotin Combined With ABVD for Hodgkin Lymphoma

Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: doxorubicin; Drug: vinblastine; Drug: dacarbazine; Drug: bleomycin
Sponsors: Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

Condition: Rheumatoid Arthritis
Interventions: Drug: CP-690,550; Drug: Atorvastatin; Drug: CP-690,550; Drug: Atorvastatin Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Safety and Efficacy of Cariprazine for Bipolar I Disorder

Conditions: Mania; Bipolar I Disorder
Interventions: Drug: Cariprazine low dose; Drug: Cariprazine high dose; Drug: Placebo
Sponsors: Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified February 2010
A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: Ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Condition: Neuroblastoma
Interventions: Drug: DFMO; Drug: Etoposide
Sponsors: University of Vermont; Cancer Prevention Pharmaceuticals; University of Arizona; University of Hawaii; University of Hawaii Cancer Research Center
Recruiting - verified February 2010
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

Condition: Congestive Heart Failure
Interventions: Drug: Lixivaptan; Drug: Placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC
Recruiting - verified February 2010
Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty

Condition: Postoperative Pain
Interventions: Drug: Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride); Drug: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Sponsor: QRxPharma Inc.
Recruiting - verified February 2010
Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

Conditions: Vaginosis, Bacterial; Vaginal Infection
Interventions: Drug: GW05; Drug: GW05; Drug: GW05; Drug: Metronidazole
Sponsor: Graceway Pharmaceuticals, LLC
Recruiting - verified March 2010
Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Intervention: Drug: Bardoxolone methyl (amorphous dispersion)
Sponsor: Reata Pharmaceuticals, Inc.
Recruiting - verified March 2010
Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders

Condition: Hepatitis C Virus Infection
Intervention: Drug: CTS-1027, Pegylated Interferon, Ribavirin
Sponsor: Conatus Pharmaceuticals Inc.
Recruiting - verified February 2010
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Ixabepilone + Carboplatin Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Carboplatin
Sponsor: US Oncology Research
Recruiting - verified February 2010
Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Conditions: Pulmonary Disease, Chronic Obstructive; Chronic Obstructive Pulmonary Disease
Interventions: Drug: FF Inhalation Powder; Drug: FF/GW642444 Inhalation Powder; Drug: GW642444 Inhalation Powder; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Conditions: Pulmonary Disease, Chronic Obstructive; Chronic Obstructive Pulmonary Disease
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: Placebo; Drug: FF Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide/formoterol fumarate combination; Drug: aclidinium bromide/formoterol fumarate combination; Drug: aclidinium bromide; Drug: formoterol fumarate; Drug: placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Condition: Schizophrenia
Interventions: Drug: LY2140023; Drug: Placebo; Drug: Standard of Care
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
A Study for Patients With Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: LY2605541; Drug: Insulin glargine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

Condition: Hypertriglyceridemia
Interventions: Drug: AMR101 (ethyl icosapentate); Drug: AMR101 (ethyl icosapentate); Drug: Placebo
Sponsor: Amarin Pharma Inc.
Recruiting - verified February 2010
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Condition: Gastro-Intestinal Cancer
Interventions: Drug: 5-FU; Drug: Leucovorin; Drug: 5-FU; Drug: Irinotecan; Drug: Brivanib; Drug: Brivanib; Drug: Brivanib
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Condition: Hypertriglyceridemia
Interventions: Drug: AMR101 (ethyl icosapentate); Drug: AMR101 (ethyl icosapentate); Drug: Placebo
Sponsor: Amarin Pharma Inc.
Recruiting - verified February 2010
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: sitagliptin
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN5401; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified February 2010
A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects

Condition: HIV Infections
Intervention: Drug: Kaletra and Intelence Tablets
Sponsors: Therapeutic Concepts; Abbott; Tibotec, Inc; BluKyne
Recruiting - verified January 2010
To Assess the Long-term Safety, Efficacy and Tolerability of Inhaled Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Aclidinium bromide; Drug: Placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435

Condition: Hepatitis C Virus
Intervention: Drug: TMC435
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation

Conditions: Pregnancy; Unexplained Infertility
Interventions: Drug: Letrozole (aromatase inhibitor); Drug: Clomiphene Citrate; Drug: Follicle Stimulating Hormone (gonadotropin)
Sponsors: Yale University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Penn State University; University of Colorado, Denver; University of Michigan; University of Pennsylvania; University of Texas; University of Vermont; Wayne State University
Not yet recruiting - verified March 2010
Third Eye Retroscope Randomized Clinical Evaluation

Condition: Colorectal Neoplasms
Intervention: Device: Third Eye Retroscope
Sponsor: Avantis Medical Systems
Recruiting - verified February 2010
To Assess the Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide at Two Dose Levels in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe, Stable COPD

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide; Drug: aclidinium bromide
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
AIGISRx Envelope for Prevention of Infection Following Replacement With a Cardiac Resynchronization Therapy Device (CRT)

Condition: Cardiac Rhythm Management Device Infection
Intervention:
Sponsor: TYRX, Inc.
Recruiting - verified February 2010
AIGISRx Envelope for Prevention of Infection Following Replacement With an Implantable Cardioverter-Defibrillator (ICD)

Condition: Implantable Cardioverter-Defibrillator Infection
Intervention:
Sponsor: TYRX, Inc.
Recruiting - verified February 2010
Study of MP0112 Intravitreal Injection in Patients With Diabetic Macula Edema

Condition: Diabetic Macular Edema
Intervention: Biological: MP0112
Sponsor: Molecular Partners AG
Recruiting - verified March 2010
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study is to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered Tapentadol ER at Dosages of 100 to 250 mg Twice Daily Compared With Placebo in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Conditions: Diabetic Neuropathy, Painful; Diabetic Polyneuropathy
Interventions: Drug: tapentadol extended release (ER); Drug: placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Grünenthal GmbH
Recruiting - verified February 2010
Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations

Condition: Familial Amyotrophic Lateral Sclerosis
Intervention: Drug: ISIS 333611
Sponsors: Isis Pharmaceuticals; Muscular Dystrophy Association; ALS Association
Recruiting - verified February 2010
12 Week Safety Trial of Flibanserin in Depressed Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire and Distress

Conditions: Sexual Dysfunctions, Psychological; Depression
Interventions: Drug: flibanserin 2; Drug: placebo; Drug: flibanserin 1
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Disease-modifying antirheumatic drug
Sponsor: Pfizer
Recruiting - verified March 2010
Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy

Condition: Pain
Interventions: Drug: Hydrocodone/acetaminophen extended release; Drug: Morphine Extended Release; Drug: Acetaminophen; Drug: Placebo
Sponsor: Abbott
Recruiting - verified January 2010
PR104 in Treating Patients With Refractory/Relapsed Acute Myelogenous Leukemia

Condition: Acute Myelogenous Leukemia
Intervention: Drug: PR104
Sponsor: Proacta, Incorporated
Recruiting - verified February 2010
Efficacy and Safety of EN3324 in Subjects With Chronic Low Back Pain

Condition: Chronic Low Back Pain
Interventions: Drug: EN3324; Drug: Placebo
Sponsor: Endo Pharmaceuticals
Recruiting - verified March 2010
A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Condition: Hepatitis C
Interventions: Drug: telaprevir; Drug: telaprevir; Drug: cyclosporine; Drug: cyclosporine; Drug: tacrolimus; Drug: tacrolimus
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified February 2010
Spinal Cord Stimulation With Precision® SCS System Versus Reoperation for Failed Back Surgery Syndrome

Conditions: Failed Back Surgery Syndrome; Leg Pain; Back Pain; Spinal Cord Stimulation
Interventions: Device: Precision Spinal Cord Stimulation; Procedure: Back Surgery
Sponsor: Boston Scientific Corporation
Recruiting - verified February 2010
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura

Condition: Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Intervention: Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified February 2010
SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

Condition: Familial Amyotrophic Lateral Sclerosis
Intervention: Drug: Pyrimethamine
Sponsors: Weill Medical College of Cornell University; Muscular Dystrophy Association
Recruiting - verified March 2010
Safety and Efficacy of F2695 SR in Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified February 2010
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Bionomics Limited
Recruiting - verified February 2010
Efficacy and Safety of TAK-491 and Chlorthalidone Compared to Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension.

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified March 2010
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified February 2010
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus Type 2
Interventions: Drug: EGT0001442; Drug: Placebo capsules to match EGT0001442
Sponsor: Theracos
Recruiting - verified February 2010
Clinical Outcomes of Lumbar Degenerative Disc Disease in Active-Duty U.S. Service Personnel

Condition: Degenerative Disc Disease
Intervention: Device: ProDisc™-L Total Disc Replacement (TDR)
Sponsor: Synthes Spine
Not yet recruiting - verified March 2010
A Study for Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: insulin glargine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: prednisone; Drug: vincristine sulfate; Drug: vinorelbine ditartrate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Preservative-Free Tafluprost (MK2452) for Open-Angle Glaucoma/Ocular Hypertension

Conditions: Open-Angle Glaucoma; Ocular Hypertension
Interventions: Drug: Preservative-Free MK2452 (Tafluprost); Drug: Comparator: timolol
Sponsor: Merck
Recruiting - verified March 2010
A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

Condition: HIV Infections
Interventions: Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR); Drug: 3-4 commercially available antiretroviral drugs
Sponsor: Myriad Pharmaceuticals
Recruiting - verified March 2010
Cardiac Safety Study of Brentuximab Vedotin (SGN-35).

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Clinical Evaluation of the PROGENSA(R) PCA3 Assay in Men With a Previous Negative Biopsy Result

Condition: Prostatic Neoplasms
Intervention: Other: PCA3 Assay
Sponsor: Gen-Probe, Incorporated
Recruiting - verified March 2010
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

Condition: Hodgkin Lymphoma
Intervention: Drug: Everolimus (RAD001)
Sponsor: Novartis
Recruiting - verified March 2010
Polysomnography Study of MK6096 in Patients With Primary Insomnia

Condition: Primary Insomnia
Interventions: Drug: MK6096 2.5 mg and placebo; Drug: Comparator: MK6096 5 mg and placebo; Drug: Comparator: MK6096 10 mg and placebo; Drug: Comparator: MK6096 20 mg and placebo
Sponsor: Merck
Recruiting - verified March 2010
A Long Term Safety Study of MK4305 in Patients With Primary Insomnia

Condition: Insomnia
Interventions: Drug: MK4305; Drug: Comparator: Placebo to MK4305
Sponsor: Merck
Recruiting - verified March 2010
A Combination Therapy Study of MK2206 and AZD6244 in Patients With Advanced Solid Tumors

Condition: Locally Advanced or Metastatic Solid Tumors
Intervention: Drug: MK2206 plus AZD6244
Sponsors: Merck; AstraZeneca
Recruiting - verified March 2010
A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-263

Conditions: Lymphoma; Chronic Lymphocytic Leukemia; Solid Tumors
Interventions: Drug: ABT-263; Drug: Ketoconazole
Sponsor: Abbott
Recruiting - verified January 2010
Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1)

Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (SCH 503034); Drug: erythropoietin; Biological: Peginterferon alfa-2b (SCH 54031); Drug: Ribavirin (SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Intravenous BI 6727 in 2nd Line Treatment of Urothelial Cancer

Condition: Neoplasms
Intervention: Drug: BI 6727, IV infusion
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection

Condition: Cervical Intraepithelial Neoplasia
Interventions: Drug: RO5217790; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Donor Lymphocytes in Preventing and Treating Cytomegalovirus Infection or Adenovirus Infection in Patients Who Have Undergone Umbilical Cord Blood Transplant

Condition: Cancer
Interventions: Biological: allogeneic CMV/AdV-specific cytotoxic T lymphocytes; Other: laboratory biomarker analysis
Sponsors: Baylor College of Medicine; National Cancer Institute (NCI)
Recruiting - verified December 2009
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne

Condition: Acne Vulgaris
Interventions: Drug: Tazarotene foam; Drug: Vehicle Foam
Sponsor: Stiefel, a GSK Company
Recruiting - verified February 2010
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Condition: Leukemia
Intervention: Drug: AEG35156
Sponsor: Aegera Therapeutics
Recruiting - verified February 2010
AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma

Condition: Asthma
Interventions: Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: RO5095932; Drug: Placebo; Drug: RO5095932; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Efficacy of the Aspen Spinous Process System in Anterior Lumbar Interbody Fusion (ALIF)

Condition: Degenerative Disc Disease
Interventions: Device: Aspen Spinous Process System; Device: Pedicle Screw Fixation
Sponsor: Lanx, Inc.
Recruiting - verified March 2010
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Combivent Respimat; Drug: Combivent CFC-MDI; Drug: Atrovent HFA + Albuterol HFA
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
A Dose Escalation Study of an Antibody in Patients With Advanced Cancers

Condition: Advanced Cancers
Intervention: Drug: MABp1
Sponsor: XBiotech, Inc.
Recruiting - verified March 2010
Safety and Efficacy of Positron Emission Tomography Imaging With BAY94-9172 (ZK 6013443)

Condition: Alzheimer Disease
Intervention: Drug: BAY94-9172
Sponsor: Bayer
Recruiting - verified February 2010
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052; Drug: BMS-650032; Drug: pegylated-interferon-α; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Evaluating an Interactive Cancer Communication System (ICCS) in Lung Cancer

Condition: Lung Cancer, Stage IIIb or IV
Intervention: Other: CHESS website for lung cancer patient + internet access if needed
Sponsors: University of Wisconsin, Madison; Harry Gray Cancer Center Hartford Hospial; M.D. Anderson Cancer Center; University of Illinois; University of Wisconsin Carbone Cancer Center
Recruiting - verified March 2010
BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: Placebo; Drug: BIBF 1120
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System

Conditions: Back Pain; Chronic Low Back Pain; Internal Disc Disruption; Degenerative Disc Disease
Interventions: Biological: Biostat System; Drug: Sodium Chloride Injection
Sponsor: Spinal Restoration, Inc.
Recruiting - verified March 2010
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: GW642444 Inhalation Powder; Drug: FF/GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

Condition: Asthma
Interventions: Drug: Fluticasone Furoate/GW642444; Drug: Fluticasone propionate
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
A Pharmacokinetic/Pharmacodynamic Study of Intravenous and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis on Methotrexate

Conditions: Arthritis; Rheumatoid Arthritis
Interventions: Biological: CDP6038; Biological: CDP6038; Biological: CDP6038; Biological: CDP6038; Biological: CDP6038; Biological: CDP6038; Other: Placebo IV; Other: Placebo SC
Sponsor: UCB, Inc.
Recruiting - verified March 2010
To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

Condition: Neoplasms
Intervention: Drug: BAY79-4620
Sponsor: Bayer
Recruiting - verified March 2010
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tociliumab; Drug: methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Condition: Onychomycosis
Interventions: Drug: IDP-108; Drug: Vehicle
Sponsor: Dow Pharmaceutical Sciences
Recruiting - verified March 2010
Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Condition: Onychomycosis
Interventions: Drug: IDP-108; Drug: Vehicle
Sponsor: Dow Pharmaceutical Sciences
Recruiting - verified March 2010
A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease

Condition: COPD
Intervention: Drug: R7103
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875 6.25 mg; Drug: TAK-875 25 mg; Drug: TAK-875 50 mg; Drug: TAK-875 100 mg; Drug: TAK-875 200 mg; Drug: Glimepiride 2 mg or 4mg; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma

Condition: Melanoma
Interventions: Drug: Tasisulam; Drug: Paclitaxel
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

Conditions: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases
Interventions: Drug: golimumab; Drug: golimumab or placebo; Drug: golimumab or placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain

Condition: Abdominal Pain Upper
Interventions: Drug: REGN475/SAR164877; Drug: Placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified February 2010
Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

Condition: Type 2 Diabetes Mellitus (T2DM)
Interventions: Drug: Dapagliflozin; Drug: Metformin XR; Drug: Glucophage
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified January 2010
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Keryx / AOI Pharmaceuticals, Inc.; Dana-Farber Cancer Institute
Recruiting - verified March 2010
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Conditions: Acute Coronary Syndrome; Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease
Interventions: Drug: Darapladib 160 mg; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

Condition: Asthma
Intervention: Biological: Mepolizumab (treatment) - Severe asthma
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

Condition: Major Depressive Disorder
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

Conditions: Haemophilus Influenzae Type B Related Disease; Pneumonia; Meningitis; Cellulitis; Osteomyelitis; Epiglottis
Interventions: Biological: InfanrixTM; Biological: GSK Biologicals' Haemophilus inluenzae type b vaccine (GSK 208108); Biological: ActHIBTM; Biological: PentacelTM; Biological: PediarixTM; Biological: PrevnarTM; Biological: RotarixTM; Biological: EngerixTM-B
Sponsor: GlaxoSmithKline
Not yet recruiting - verified March 2010
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

Condition: Cystitis, Interstitial
Interventions: Biological: Tanezumab; Biological: Tanezumab; Biological: Tanezumab; Biological: Tanezumab; Other: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)

Condition: Sickle Cell Disease
Interventions: Other: High Demand / Low Infusion; Other: PCA Dosing Plan
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Eltrombopag for Post Transplant Thrombocytopenia

Condition: Thrombocytopenia
Interventions: Drug: Eltrombopag; Drug: Placebo
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

Conditions: Lymphoma; Chronic Lymphocytic Leukemia; Solid Tumors
Interventions: Drug: ABT-263; Drug: erlotinib; Drug: irinotecan
Sponsor: Abbott
Recruiting - verified February 2010
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified March 2010
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: flibanserin; Drug: placebo; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
TAXUS Libertē Post Approval Study

Condition: Coronary Artery Disease
Interventions: Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent; Drug: prasugrel; Drug: placebo; Drug: aspirin
Sponsors: Boston Scientific Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified February 2010
Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder

Condition: Posttraumatic Stress Disorder (PTSD)
Interventions: Drug: orvepitant; Other: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Linagliptin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis

Condition: Psoriasis
Interventions: Drug: Etanercept ONLY; Drug: Methotrexate and Etanercept
Sponsors: Amgen; Immunex Corporation
Recruiting - verified March 2010
A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip
Interventions: Other: Tanezumab 2.5 mg; Other: Tanezumab 5 mg; Other: Tanezumab 10 mg
Sponsor: Pfizer
Recruiting - verified February 2010
Safety and Tolerability of TAK-491 Plus Chlorthalidone Compared to Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Essential Hypertension

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
The Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis to Assess the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo; Biological: Certolizumab pegol
Sponsor: UCB, Inc.
Recruiting - verified March 2010
6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: INSULIN GLARGINE (HOE901); Drug: Neutral Protamine Hagedorn (NPH) insulin
Sponsor: Sanofi-Aventis
Recruiting - verified February 2010
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Conditions: Pain; Diabetic Neuropathy, Painful
Interventions: Drug: Placebo; Drug: JNJ-42160443
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Novartis H1N1 Vaccine in Pregnant Women

Condition: Influenza
Intervention: Biological: Inactivated H1N1 Vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2009
H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

Condition: Influenza
Intervention: Biological: Inactivated Influenza H1N1 vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
A Study of LY573636 in Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Drug: LY573636
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

Condition: Restless Legs Syndrome
Interventions: Drug: pregabalin; Drug: placebo; Drug: pramipexole
Sponsor: Pfizer
Recruiting - verified February 2010
Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
Sponsor: Lung Rx
Recruiting - verified February 2010
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Condition: Coronary Artery Disease
Interventions: Drug: Apadenoson; Drug: Adenosine
Sponsors: PGxHealth, LLC; PPD
Recruiting - verified March 2010
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Condition: Castrate-Resistant Prostate Cancer
Intervention: Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsor: Celgene Corporation
Recruiting - verified March 2010
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds

Condition: Human Papillomavirus Infection
Interventions: Biological: V503; Biological: Comparator: Menactra™ (Concomitant); Biological: Comparator: Adacel™ (concomitant); Biological: Comparator: Menactra™ (Non-Concomitant); Biological: Comparator: Adacel™ (Non-concomitant)
Sponsor: Merck
Recruiting - verified March 2010
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia
Intervention: Drug: Compound AC220
Sponsor: Ambit Biosciences Corporation
Recruiting - verified March 2010
RELIEF: Healthcase Utilization and Outcomes of FinESS Treatment in the Office

Condition: Rhinosinusitis
Intervention: Device: FinESS Sinus Treatment
Sponsor: Entellus Medical, Inc.
Recruiting - verified March 2010
Carboplatin and Paclitaxel Combined With Cetuximab and/or Cixutumumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: cetuximab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

Conditions: Hepatitis; Hepatitis C
Interventions: Drug: Filibuvir; Drug: Filibuvir; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain

Conditions: Pain; Back Pain; Low Back Pain; Back Pain With Radiation
Interventions: Drug: Oxycodone IR; Drug: NUCYNTA
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal
Recruiting - verified February 2010
Tanezumab in Osteoarthritis of the Hip or Knee

Condition: Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: oxycodone; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Matching placebo
Sponsor: Shire Pharmaceutical Development
Recruiting - verified February 2010
Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Fluticasone propionate/salmeterol combination product; Drug: Salmeterol; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Condition: Neoplasms
Interventions: Drug: RG1507; Drug: RAD001
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052; Drug: Ortho Tri-Cyclen®
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Prostate Cancer Symptom Management for Low Literacy Men

Condition: Localized Prostate Cancer
Interventions: Behavioral: PC-PEP - Prostate Cancer Patient Education Program; Behavioral: Usual care
Sponsors: Baylor College of Medicine; American Cancer Society; Michael Debakey Veterans Affairs Medical Center
Recruiting - verified March 2010
Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

Conditions: Lymphoma; Chronic Lymphocytic Leukemia; Solid Tumors
Interventions: Drug: ABT-263; Drug: ABT-263; Drug: ABT-263; Drug: ABT-263
Sponsors: Abbott; Genentech
Recruiting - verified December 2009
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Conditions: Hepatitis C; HIV Infections
Interventions: Drug: telaprevir or matching placebo; Drug: telaprevir or matching placebo; Biological: peginterferon alfa-2a; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee

Condition: Osteoarthritis, Knee
Interventions: Drug: PF-04457845; Drug: PF-04457845; Drug: Naproxen; Drug: Naproxen
Sponsor: Pfizer
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis - The ADAMO Trial

Conditions: Low Bone Mass; Low Bone Mineral Density; Males With Osteoporosis; Osteopenia; Osteoporosis
Interventions: Drug: 60 mg denosumab; Other: Placebo
Sponsor: Amgen
Recruiting - verified February 2010
Oxycodone User Registry (OUR)

Condition: Pain
Intervention: Drug: oxycodone immediate release (OXYRX)
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
The Dual Antiplatelet Therapy Study (DAPT Study)

Condition: Coronary Artery Disease
Interventions: Drug: Placebo & Aspirin; Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
Sponsors: Harvard Clinical Research Institute; Abbott; Boston Scientific Corporation; Bristol-Myers Squibb; Sanofi-Synthelabo; Cordis Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.; Medtronic
Recruiting - verified March 2010
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PF-03463275; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Investigation of Genetic Determinants of Capecitabine Toxicity

Condition: Breast Cancer
Interventions: Other: Side-effect questionnaires; Other: research blood samples
Sponsors: University of Chicago; Translational Breast Cancer Reserach Consortium; National Institutes of Health (NIH)
Recruiting - verified February 2010
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin glargine + preprandial lispro insulin; Biological: albiglutide + insulin glargine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

Condition: Gastroesophageal Reflux Disease
Interventions: Drug: arbaclofen placarbil; Drug: Placebo
Sponsor: XenoPort, Inc.
Recruiting - verified March 2010
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

Condition: Influenza Infection
Interventions: Biological: GSK2340273A; Biological: GSK2340274A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

Condition: Parkinson's Disease
Interventions: Drug: IPX066; Drug: regular carbidopa-levodopa
Sponsor: IMPAX Laboratories, Inc.
Recruiting - verified March 2010
Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Condition: Psoriasis
Interventions: Drug: AMG 827; Drug: AMG 827; Drug: AMG 827; Drug: AMG 827; Drug: Placebo
Sponsor: Amgen
Not yet recruiting - verified March 2010
TMC435-TiDP16-C206: A Safety and Efficacy Study in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Condition: Hepatitis C
Interventions: Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 placebo /Peg IFNa2A/Ribavirin
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Conditions: Chronic Allograft Nephropathy; Chronic Kidney Disease; Chronic Renal Failure; Disordered Mineral Metabolism; End Stage Renal Disease; Hyperparathyroidism; Hypophosphatemia; Kidney Disease; Kidney Transplantation; Post Renal Transplantation
Interventions: Drug: Placebo; Drug: Cinacalcet
Sponsor: Amgen
Not yet recruiting - verified March 2010
Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne

Condition: Severe Nodular Acne
Intervention: Drug: CIP-Isotretinoin and Isotretinoin
Sponsor: Cipher Pharmaceuticals Inc.
Recruiting - verified February 2010
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsor: Medivation, Inc.
Recruiting - verified March 2010
To Evaluate the Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

Condition: Gastroesophageal Reflux
Interventions: Drug: Rabeprazole sodium capsules; Drug: placebo; Drug: Rabeprazole sodium capsules
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified February 2010
A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain

Condition: Sciatica
Interventions: Drug: REGN475; Drug: REGN475; Drug: Placebo Injection
Sponsors: Regeneron Pharmaceuticals; Sanofi-Aventis
Recruiting - verified February 2010
Infusion of Expanded Cord Blood T Cells

Conditions: Stem Cell Transplantation; Leukemia; Lymphoma; Pediatrics
Interventions: Radiation: Total Body Irradiation (TBI); Drug: Melphalan; Drug: Thiotepa; Drug: Fludarabine; Drug: Rituximab; Drug: Etoposide; Drug: Anti-thymocyte globulin (ATG); Drug: Mycophenolate Mofetil (MMF); Drug: Tacrolimus; Procedure: Cord Blood Infusion; Drug: G-CSF; Procedure: Ex vivo expanded T cell Infusion
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Safety Study of Probiotics in Adults With Irritable Bowel Syndrome

Condition: Irritable Bowel Syndrome
Intervention: Biological: Probiotic
Sponsors: Baylor College of Medicine; National Institute of Nursing Research (NINR); University of Washington
Recruiting - verified March 2010
Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

Condition: Chronic Hepatitis C
Interventions: Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone

Condition: Diabetes Mellitus, Type II
Interventions: Drug: Placebo; Drug: Dutogliptin
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepiride; Drug: JNJ-28431754
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults

Condition: Asthma
Interventions: Biological: MEDI-528; Biological: MEDI-528; Biological: MEDI-528; Other: Placebo
Sponsor: MedImmune LLC
Recruiting - verified March 2010
Muscle Mass During Space Exploration

Condition: Sarcopenia
Interventions: Dietary Supplement: Leucine; Dietary Supplement: Leucine
Sponsors: The University of Texas, Galveston; National Space Biomedical Research Institute
Recruiting - verified March 2010
Autologous CD19-specific T Cells Infusion

Conditions: Lymphoma; B-Cell Lymphoma
Interventions: Procedure: Leukapheresis; Procedure: Stem Cell Transplant; Procedure: CD19-specific T Cell Infusion; Drug: IL-2; Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Rituximab
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting - verified February 2010
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Conditions: Adenocarcinoma; Advanced Breast Cancer; Advanced Metastatic Breast Cancer; ErbB2+; Her2+; Invasive Breast Cancer; Metastatic ErbB2
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis

Conditions: Anemia; Chronic Kidney Disease
Interventions: Drug: MK2578; Drug: Comparator: MK2578; Drug: Comparator: MK2578; Drug: Comparator: darbepoetin alfa
Sponsor: Merck
Recruiting - verified March 2010
A Study in Patients With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: LY2439821; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: LY2216684
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients

Condition: Advanced Cancer
Interventions: Drug: Testosterone; Drug: Placebo
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Conditions: Pain; Neuralgia, Postherpetic; Neuralgia; Mononeuropathies
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: placebo; Drug: rontalizumab
Sponsor: Genentech
Recruiting - verified February 2010
Presbyopia-Correcting Intraocular Lenses (IOLs)

Condition: Cataract
Interventions: Device: ReSTOR +3; Device: Crystalens HD
Sponsor: Alcon Research
Recruiting - verified February 2010
Open Label, Phase I Study in Patients With Advanced Cancer

Condition: Neoplasms
Intervention: Drug: BAY80-6946
Sponsor: Bayer
Recruiting - verified March 2010
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: RO5095932; Drug: RO5095932; Drug: placebo; Drug: metformin
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients

Condition: Osteoarthritis
Interventions: Biological: Tanezumab; Biological: Tanezumab; Other: Placebo
Sponsor: Pfizer
Not yet recruiting - verified February 2010
A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant (MK0524A)) in Patients With Dyslipidemia

Condition: Dyslipidemia
Interventions: Drug: ER niacin (+) laropiprant (ERN/LRPT); Drug: Comparator: ER niacin (+) laropiprant (ERN/LRPT); Drug: Comparator: Extended-release niacin (ERN); Drug: Comparator: Placebo to ERN/LRPT
Sponsor: Merck
Recruiting - verified March 2010
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

Condition: Pediculosis
Interventions: Drug: Malathion gel 0.5%; Drug: Permethrin 1% rinse (Nix Crème)
Sponsor: Taro Pharmaceuticals USA
Recruiting - verified March 2010
Study of Blood Samples From Newborns With Down Syndrome

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Conditions: Seasonal Influenza; Cough; Sore Throat; Nasal Congestion; Myalgia; Headache; Fatigue
Interventions: Drug: Peramivir; Drug: Peramivir
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified March 2010
A Study in Relapse Prevention of Treatment-resistant Depression

Condition: Treatment Resistant Depression
Interventions: Drug: Olanzapine and Fluoxetine combination; Drug: Fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Anterior Pituitary Hormone Replacement in Traumatic Brain Injury

Conditions: Growth Hormone Deficiency; Traumatic Brain Injury
Interventions: Drug: Genotropin; Drug: Placebo
Sponsors: The University of Texas, Galveston; The Moody Foundation
Recruiting - verified February 2010
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: warfarin; Drug: placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Duke University
Recruiting - verified February 2010
Examining Benefits of HAART Continuation in Postpartum Mothers

Condition: HIV Infections
Intervention: Drug: Highly active antiretroviral therapy (HAART)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

Condition: Subjective Tinnitus
Interventions: Drug: Neramexane mesylate; Drug: Placebo
Sponsor: Merz Pharmaceuticals GmbH
Recruiting - verified March 2010
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Condition: Head and Neck Cancer
Intervention: Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; OSI Pharmaceuticals
Recruiting - verified March 2010
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Condition: Partial Epilepsies
Intervention: Drug: Lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

Conditions: Non-small Cell Lung Cancer; Pancreatic Cancer; Solid Tumors
Intervention: Drug: GSK1120212 plus everolimus
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Alogliptin; Drug: Alogliptin; Drug: Alogliptin; Drug: Alogliptin; Drug: Alogliptin
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Condition: Myelofibrosis
Interventions: Drug: INCB018424; Drug: Placebo
Sponsor: Incyte Corporation
Recruiting - verified March 2010
Observational Prospective Registry of the Efficacy, Safety, and Adherence to Therapy of Infergen® (Interferon Alfacon 1) in Patients Chronically Infected With Hepatitis C Virus

Condition: Hepatitis C
Intervention: Drug: Infergen with or without ribavirin
Sponsor: Three Rivers Pharmaceuticals
Recruiting - verified March 2010
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
BIBW 2992 Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Interventions: Drug: BIBW 2992; Drug: BIBW 2992; Drug: Cisplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pemetrexed
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Study of Patients With Advanced Non-Small Cell Lung Cancer

Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Condition: Leukemia
Interventions: Drug: Vorinostat; Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; Merck
Recruiting - verified March 2010
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease

Conditions: Adult Polyglucoson Body Disease; Glycogen Brancher Enzyme Deficiency; Glycogen Storage Disease Type IV
Interventions: Dietary Supplement: Triheptanoin; Dietary Supplement: Vegetable Oil
Sponsor: Baylor Research Institute
Recruiting - verified February 2010
An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin

Condition: Diabetes Mellitus, Type II
Interventions: Drug: Dutogliptin; Drug: Placebo
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
A Study of the Safety and Efficacy of JNJ-39758979 in the Treatment of Adults With Asthma

Condition: Asthma
Intervention: Drug: JNJ39758979
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Condition: Factor XIII Deficiency
Intervention: Biological: FXIII Concentrate Human
Sponsor: CSL Behring
Recruiting - verified March 2010
A Study of SCH 717454 in Combination With Different Treatment Regimens in Subjects With Advanced Solid Tumors (P04722)

Condition: Neoplasms
Interventions: Drug: Regimen A: FOLFIRI (± Cetuximab), and SCH 717454; Drug: Regimen B: Carboplatin, Paclitaxel, and SCH 717454; Drug: Regimen C: Epirubicin, Cisplatin, 5-FU, and SCH 717454; Drug: Regimen D: Trastuzumab and SCH 717454; Drug: Regimen E: mTor Inhibitor (Everolimus) and SCH 717454; Drug: Regimen F: Gemcitabine (± Erlotinib), and SCH 717454
Sponsor: Schering-Plough
Recruiting - verified March 2010
A Study of Duloxetine in Patients With Osteoarthritis Knee Pain

Condition: Osteoarthritis Knee Pain
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors

Condition: Advanced Solid Tumor
Interventions: Drug: Hydroxychloroquine ( HCQ); Drug: Vorinostat (Suberoylanilide Hydroxamic Acid)
Sponsors: The University of Texas Health Science Center at San Antonio; Merck
Recruiting - verified February 2010
Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: liraglutide; Drug: placebo; Drug: liraglutide; Drug: placebo
Sponsor: Novo Nordisk
Recruiting - verified February 2010
Safety and Efficacy of Reserpine Alone and in Combination With Fluoxetine in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Reserpine and fluoxetine
Sponsor: University of Texas Southwestern Medical Center
Recruiting - verified July 2009
A Study of LY2189102 in Patients With Type 2 Diabetes

Condition: Type 2 Diabetes
Interventions: Drug: LY2189102; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage III or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; The Indiana University Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2010
College Students and Smoking Cessation

Conditions: Smoking Cessation; Habits; Smoking
Interventions: Behavioral: Survey; Behavioral: Counseling; Behavioral: Survey; Behavioral: Counseling
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

Condition: Asthma
Interventions: Drug: QMF149 Twisthaler®; Drug: Mometasone Twisthaler®
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

Condition: Alzheimer's Disease
Intervention: Drug: Dimebon
Sponsors: Pfizer; Medivation, Inc.
Recruiting - verified March 2010
AZD2066 Neuropathic Pain - Mechanical Hypersensitivity

Conditions: Neuropathic Pain; Mechanical Hypersensitivity
Interventions: Drug: AZD2066; Drug: Placebo
Sponsors: AstraZeneca; Quintiles
Recruiting - verified March 2010
A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care

Conditions: Type 2 Diabetes; Major Depressive Disorder
Interventions: Behavioral: Diabetes and depression intervention; Behavioral: Diabetes intervention
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified March 2010
Study of XL184 in Adults With Advanced Malignancies

Conditions: Solid Tumors; Cancer
Interventions: Drug: XL184; Drug: Placebo; Drug: XL184
Sponsor: Exelixis
Recruiting - verified February 2010
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg; Drug: Sham
Sponsors: Regeneron Pharmaceuticals; Bayer
Recruiting - verified February 2010
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

Condition: Postmenopausal Osteoporosis
Interventions: Drug: Ibandronate; Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

Conditions: Neoplasms; Unresectable Metastatic Cutaneous Melanoma
Intervention: Biological: Immunotherapeutic GSK2132231A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Conditions: Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: obatoclax mesylate; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

Condition: Schizophrenia
Interventions: Drug: oral risperidone; Drug: paliperidone palmitate
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Trial To Study The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

Condition: Epilepsy
Interventions: Drug: Lacosamide; Drug: Lacosamide; Drug: Lacosamide
Sponsor: UCB, Inc.
Recruiting - verified February 2010
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Condition: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Drug: Vc-RCHOP; Drug: RCHOP
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Condition: Diabetes Mellitus, Type 2
Intervention: Drug: linagliptin QD for 7 days
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

Condition: Metastatic Colorectal Cancer
Intervention: Drug: EZN-2208, Cetuximab and Irinotecan
Sponsor: Enzon Pharmaceuticals, Inc.
Recruiting - verified March 2010
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

Condition: Bronchiectasis
Interventions: Drug: Cipro (Ciprofloxacin, BAYQ3939); Drug: Placebo
Sponsors: Bayer; Novartis
Recruiting - verified February 2010
BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

Condition: HIV
Interventions: Drug: atazanavir/raltegravir; Drug: atazanavir/raltegravir; Drug: atazanavir/tenofovir/emtricitabine
Sponsor: Community Research Initiative of New England
Recruiting - verified February 2010
Abatacept Versus Adalimumab Head-to-Head

Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Adalimumab
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Placebo; Drug: OROS MPH
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Trial Evaluating the Safety and Effectiveness of NUBAC™ Disc Arthroplasty

Condition: Degenerative Disc Disease
Intervention: Device: NUBAC™
Sponsor: Pioneer Surgical Technology, Inc.
Recruiting - verified February 2010
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Not Responded to Treatment

Conditions: Brain and Central Nervous System Tumors; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

Condition: Hypertension
Interventions: Drug: Telmisartan 80mg; Drug: Telmisartan80mg/hydrochlorothiazide25mg; Drug: Telmisartan80mg/hydrochlorothiazide25mg; Drug: Telmisartan
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

Condition: Acute Myeloid Leukemia
Interventions: Drug: AZD1152; Drug: LDAC (low dose cytosine arabinoside)
Sponsor: AstraZeneca
Recruiting - verified March 2010
XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)

Condition: Degenerative Disc Disease
Interventions: Device: XL TDR; Other: Lumbar fusion surgery
Sponsor: NuVasive
Recruiting - verified February 2010
A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

Condition: Solid Cancer
Intervention: Drug: cabazitaxel (XRP6258)
Sponsor: Sanofi-Aventis
Recruiting - verified February 2010
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride; Drug: Placebo
Sponsor: Amicus Therapeutics
Recruiting - verified March 2010
Long Term Safety Study of Tanezumab in Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg; Biological: Tanezumab 10 mg
Sponsor: Pfizer
Recruiting - verified March 2010
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

Condition: Adrenocortical Carcinoma (ACC)
Interventions: Drug: OSI-906; Other: Placebo
Sponsor: OSI Pharmaceuticals
Recruiting - verified December 2009
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis

Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate plus leuprolide acetate plus prednisone; Drug: leuprolide acetate
Sponsor: Cougar Biotechnology, Inc.
Recruiting - verified March 2010
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: LY2216684; Drug: Methylphenidate; Drug: Placebo (tablet); Drug: Placebo (capsule)
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

Condition: Schizophrenia and Predominant Negative Symptoms
Interventions: Drug: SPD489 (lisdexamfetamine dimesylate); Drug: Placebo matching SPD489 (lisdexamfetamine dimesylate)
Sponsor: Shire Pharmaceutical Development
Recruiting - verified March 2010
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Teplizumab (MGA031); Drug: Placebo
Sponsors: MacroGenics; Eli Lilly and Company
Recruiting - verified March 2010
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Condition: Leukemia-relapsed or Refractory
Interventions: Drug: GSK1120212; Drug: GSK1120212
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

Condition: Cancer
Intervention: Drug: MPC-3100 (an Hsp90 inhibitor)
Sponsor: Myriad Pharmaceuticals
Recruiting - verified March 2010
Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood and Bone Marrow Samples From Patients With Myeloma, Waldenstrom's Macroglobulinemia, Amyloidosis, or Monoclonal Gammopathy of Undetermined Significance

Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors

Conditions: Diabetic Nephropathy; Chronic Kidney Disease
Interventions: Drug: Placebo for Atrasentan 0,2 mg/mL solution; Drug: 0.25 mg Atrasentan QD; Drug: 0.75 mg Atrasentan QD; Drug: 1.75 mg Atrasentan QD
Sponsor: Abbott
Recruiting - verified January 2010
Study to Evaluate 24 Hour Blood Sugar Control in Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared to Subjects Taking Metformin XR 1500 mg Uptitrated to Metformin XR 2000 mg

Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Metformin XR; Drug: Placebo matching Metformin 500 mg; Drug: Metformin XR; Drug: Placebo matching Saxagliptin 5 mg
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2010
A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-small Cell Lung Cancer
Interventions: Biological: IMC-3G3; Drug: Paclitaxel; Drug: carboplatin
Sponsor: ImClone LLC
Recruiting - verified March 2010
Study Evaluating Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in ErbB-2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsor: Wyeth
Recruiting - verified March 2010
Virology Follow up Study in Subjects Previously Treated With Telaprevir

Condition: Hepatitis C
Intervention:
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

Condition: Variola Major (Smallpox)
Interventions: Biological: IMVAMUNE® (liquid, intradermal); Biological: IMVAMUNE® (lyophilized); Biological: IMVAMUNE® (liquid, subcutaneous)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])

Conditions: Hereditary Angioedema; C1 Esterase Inhibitor Deficiency
Intervention: Biological: C1 inhibitor (human)
Sponsor: ViroPharma
Recruiting - verified August 2009
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Condition: Hereditary Angioedema
Interventions: Drug: Icatibant; Drug: Placebo
Sponsors: Jerini AG; Shire Human Genetic Therapies, Inc.
Recruiting - verified November 2009
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Ablation Versus Anti-Arrhythmic (AA) Drug Therapy for AF - Pivotal Trial

Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

Condition: Acute Coronary Syndrome
Interventions: Drug: Placebo; Drug: GW856553; Drug: GW856553
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Procedure: Lymphoseek
Sponsor: Neoprobe Corporation
Recruiting - verified February 2010
Study Evaluating the Safety and Efficacy of Bapineuzumab in Subjects With Alzheimer Disease

Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: placebo
Sponsor: Wyeth
Recruiting - verified February 2010
Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Arformoterol; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Primovist / Eovist in Renally Impaired Patients

Condition: Contrast Media
Intervention: Drug: Eovist (Primovist, BAY86-4873)
Sponsor: Bayer
Recruiting - verified March 2010
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer

Condition: Chemotherapy Induced Anemia
Interventions: Biological: Biological: ACE-011; Drug: Placebo
Sponsors: Acceleron Pharma, Inc.; Celgene Corporation
Recruiting - verified March 2010
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Conditions: Colorectal Cancer; Head and Neck Cancer; Neoplasm Metastasis
Interventions: Drug: BMS-754807; Drug: cetuximab (Erbitux®)
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Conditions: Stomach Neoplasms; Esophageal Neoplasms
Interventions: Drug: BMS-833923; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified December 2009
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Conditions: Advanced Myelodysplastic Syndrome; Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia After MDS; Thrombocytopenia
Interventions: Drug: eltrombopag olamine; Other: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: ACT-064992 (macitentan); Drug: Placebo
Sponsor: Actelion
Recruiting - verified March 2010
Study to Test GSK256073 in Patients With Dyslipidemia

Condition: Dyslipidaemia
Interventions: Drug: Niaspan; Drug: GSK256073; Drug: GSK256073; Drug: GSK256073; Drug: Placebo; Drug: GSK256073; Drug: GSK256073
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Imatinib in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: QTI571; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors: Bayer; Onyx Pharmaceuticals; OSI Pharmaceuticals; Hoffmann-La Roche
Recruiting - verified March 2010
Ventavis® Registry Protocol

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Commercial Ventavis® (iloprost)
Sponsor: Actelion
Recruiting - verified March 2010
A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster

Conditions: Herpes Zoster; Shingles
Interventions: Drug: valacyclovir; Drug: FV-100; Drug: FV-100; Drug: Valacyclovir placebo; Drug: FV-100 placebo
Sponsor: Inhibitex
Recruiting - verified February 2010
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

Condition: Lymphoma
Intervention: Other: cryopreservation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Other: biologic sample preservation procedure; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Interventions: Genetic: cytogenetic analysis; Genetic: microarray analysis; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Other: biologic sample preservation procedure; Procedure: biopsy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Conditions: HIV Infections; Acquired Immunodeficiency Syndrome
Interventions: Drug: ATV/rtv 400/100mg; Drug: 48 weeks ATV/rtv 300/100mg once daily + ETR 200mg twice daily; Drug: ATV/rtv 300/100mg; Drug: TDF 300mg
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Open Label Study of Sipuleucel-T

Condition: Prostate Cancer
Intervention: Drug: Sipuleucel-T
Sponsor: Dendreon
Recruiting - verified March 2010
The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome

Condition: Rett Syndrome
Intervention:
Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting - verified April 2009
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease

Condition: Metastatic Colorectal Cancer
Interventions: Drug: CT-011; Drug: FOLFOX
Sponsor: CureTech Ltd
Recruiting - verified February 2010
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
Randomized Withdrawal Study of Desvenlafaxine Succinate Sustained Release in Outpatients With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine succinate sustained release Dose A; Drug: Placebo
Sponsor: Wyeth
Recruiting - verified February 2010
A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

Condition: Diabetes Mellitus, Type 2
Intervention: Biological: CVX-096
Sponsor: Pfizer
Recruiting - verified March 2010
Efficacy and Safety Study of Subjects That Are Taking Saxagliptin Added Onto Metformin Immediate Release (IR), Twice Daily, Compared to Subjects Taking Metformin IR Alone

Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin plus metformin IR; Drug: Placebo plus metformin IR
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified October 2009
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Condition: Factor XIII Deficiency
Intervention: Biological: FXIII Concentrate Human
Sponsor: CSL Behring
Recruiting - verified March 2010
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Effects of Pregabalin (Lyrica) on Sleep Maintenance in Subjects With Fibromyalgia

Conditions: Fibromyalgia; Sleep Disorders
Interventions: Drug: Pregabalin; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified December 2009
A Study of Patients With Relapsing Remitting Multiple Sclerosis

Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: LY2127399; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Intervention: Drug: CNTO 3649; Placebo
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
A Trial of CM-AT in Children With Autism

Condition: Autism
Interventions: Drug: CM-AT; Drug: Placebo
Sponsor: Curemark
Recruiting - verified March 2010
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

Condition: Depression
Interventions: Other: Placebo; Drug: orvepitant
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas

Conditions: Glial Cell Tumors; Malignant Gliomas
Interventions: Drug: Valproic acid; Drug: Bevacizumab; Radiation: Radiation therapy
Sponsor: Baylor College of Medicine
Recruiting - verified February 2010
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

Conditions: Cancer; Melanoma; Solid Tumor Cancer
Interventions: Drug: Midazolam; Drug: GSK2118436; Drug: GSK2118436
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: ixabepilone
Sponsor: Eisai Inc.
Recruiting - verified March 2010
Study Evaluating the Effects of Neratinib in Women With Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Conditions: Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension
Intervention: Drug: Ambrisentan or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone in Post Menopausal Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Bosutinib; Drug: Letrozole
Sponsor: Wyeth
Recruiting - verified March 2010
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

Condition: Herpes Labialis
Intervention: Drug: Famciclovir
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

Condition: Myocardial Infarction
Interventions: Drug: Prochymal®; Drug: Placebo
Sponsor: Osiris Therapeutics
Recruiting - verified February 2010
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Condition: Euvolemic Hyponatremia
Interventions: Drug: Lixivaptan; Drug: Placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC; Biogen Idec
Recruiting - verified February 2010
Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration.

Conditions: Age-Related Maculopathy; Age-Related Maculopathies; Eye Diseases; Retinal Degeneration; Macular Degeneration
Interventions: Biological: RN6G; Biological: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Quality of Life in Men With High Risk Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Behavioral: QOL Questionnaire
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
A Study of Tanezumab in Adults With Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 10 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 5 mg IV; Drug: Placebo for naproxen; Biological: Placebo for tanezumab; Drug: Naproxen; Biological: Placebo for tanezumab; Drug: Placebo for naproxen
Sponsor: Pfizer
Recruiting - verified February 2010
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Thiazolidinedione Intervention With Vitamin D Evaluation

Conditions: Cardiovascular Disease; Type 2 Diabetes Mellitus
Interventions: Drug: pioglitazone; Drug: placebo; Dietary Supplement: vitamin D; Dietary Supplement: placebo; Drug: rosiglitazone
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Condition: Occult Primary
Interventions: Drug: belinostat, carboplatin, paclitaxel; Drug: carboplatin, paclitaxel
Sponsor: TopoTarget A/S
Recruiting - verified March 2010
The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633AM1)

Conditions: Coronary Artery Bypass; Myocardial Infarction; Ventricular Dysfunction, Left; Stroke; Cardiopulmonary Bypass
Interventions: Drug: Acadesine; Drug: Normal Saline
Sponsor: Schering-Plough
Recruiting - verified March 2010
Plating Clavicle Fractures

Condition: Clavicle Fracture, Non Union/Malunion
Interventions: Procedure: superior plate; Procedure: anterior-inferior plate
Sponsors: United States Army Institute of Surgical Research; William Beaumont Army Medical Center
Recruiting - verified February 2010
Model 4195 Left Ventricular (LV) Lead Chronic Performance Study

Condition: Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: RO5024048; Drug: Pegasys; Drug: Pegasys; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics

Condition: Diabetic Neuropathies
Interventions: Drug: Carisbamate 800 mg/d; Drug: Pregabalin 300 mg/d; Drug: Placebo; Drug: Carisbamate 1,200 mg/d
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
PDE5 Inihibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsor: Bayer
Recruiting - verified March 2010
Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Conditions: Relapsed Neuroblastoma; Refractory Neuroblastoma; Relapsed Medulloblastoma; Refractory Medulloblastoma
Intervention: Drug: TPI 287
Sponsors: University of Vermont; Archer Biosciences, Inc.
Recruiting - verified February 2010
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

Condition: Bipolar I, Depression
Intervention: Drug: lurasidone
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

Condition: Bipolar Depression
Interventions: Drug: lurasidone + (lithium or divalproex); Drug: Placebo + (lithium or divalproex)
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: imatinib mesylate
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large Cell Lymphoma

Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

Conditions: Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Interventions: Drug: Daunorubicin; Drug: Vincristine; Drug: PEG-asparaginase; Drug: Intrathecal Methotrexate; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Doxorubicin; Drug: Thioguanine
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Condition: Epilepsy With Simple or Complex Partial Onset Seizures
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Tanezumab and Nerve Function in Arthritis Patients

Condition: Osteoarthritis
Interventions: Biological: tanezumab; Biological: tanezumab; Other: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Chemotherapy or Observation in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate; Procedure: standard follow-up care
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane; Drug: Placebo, Exemestane
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Condition: Malignant Melanoma
Interventions: Drug: ABI-007; Drug: Dacarbazine
Sponsors: Abraxis BioScience Inc.; University of Arizona
Recruiting - verified August 2009
Combination Pain Therapy in HIV Neuropathy

Conditions: HIV Infections; Peripheral Neuropathy
Interventions: Drug: Duloxetine; Drug: Duloxetine placebo; Drug: Methadone; Drug: Methadone placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
Tanezumab in Osteoarthritis of the Hip or Knee (2)

Condition: Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified February 2010
A Study With Pentasa in Patients With Active Crohn's Disease

Condition: Crohn´s Disease
Interventions: Drug: Pentasa; Drug: Placebo
Sponsor: Ferring Pharmaceuticals
Recruiting - verified February 2010
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Ezetimibe/Simvastatin (MK0653A) vs Rosuvastatin vs Doubling Statin Dose in Patients With Cardiovascular Disease and Diabetes Mellitus

Conditions: Cardiovascular Disorder; Diabetes Mellitus
Interventions: Drug: ezetimibe (+) simvastatin; Drug: Comparator: simvastatin 40 mg or atorvastatin 20 mg; Drug: Comparator: rosuvastatin; Drug: Comparator: atorvastatin 10 mg or simvastatin 20 mg
Sponsor: Merck
Recruiting - verified March 2010
First Line Hepato Cellular Carcinoma (HCC)

Condition: Hepato Cellular Carcinoma (HCC)
Interventions: Drug: Brivanib; Drug: Placebo; Drug: Sorafenib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Clinical Studies on Bile Acids in Barrett's Esophagus

Condition: Gastroesophageal Reflux Disease
Intervention: Procedure: Esophageal biopsy
Sponsor: Department of Veterans Affairs
Recruiting - verified March 2010
Neurosciences Research Repository

Condition: Neurological Conditions
Intervention: Other: tissue and data repository
Sponsors: The University of Texas Health Science Center, Houston; The Vivian L. Smith Center for Neurologic Research
Recruiting - verified March 2010
Anemia Treatment for Advanced NSCLC Patients Receiving Chemotherapy

Conditions: Non-small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsor: Amgen
Recruiting - verified March 2010
Growth Factor Signature (GFS) Pilot Study

Conditions: Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia; Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia
Intervention: Other: Comparator: Biomarker evaluation
Sponsor: Merck
Recruiting - verified March 2010
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Subjects With Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Alogliptin and metformin; Drug: Alogliptin and metformin; Drug: Glipizide and metformin
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Safety & Efficacy Study in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

Conditions: Insomnia; Attention Deficit Hyperactivity Disorder
Interventions: Drug: eszopiclone; Drug: eszopiclone; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Condition: Optic Neuritis
Interventions: Drug: Glatiramer Acetate (Copaxone); Drug: placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified February 2010
Long Term Safety Study in Children and Adolescents With Attention Deficit Hyperactivity Disorder -Associated Insomnia

Conditions: Insomnia; Attention Deficit Hyperactivity Disorder
Intervention: Drug: eszopiclone
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for the Treatment of Rheumatoid Arthritis in Patients on Other Background Arthritis Medications

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Virtual Reality and D-Cycloserine in Combat Related Psycological Trauma in Burn Service Members

Condition: Psychological Trauma
Interventions: Other: VR (Virtual reality); Drug: D-Cycloserine
Sponsor: United States Army Institute of Surgical Research
Recruiting - verified February 2010
Phase 3 Study Comparing 2 Doses of CP-690,550 and the Active Comparator, Humira (Adalimumab) vs. Placebo for Treatment of Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: CP 690,550; Drug: CP-690,550; Other: Placebo; Other: Placebo; Biological: Biologic TNFi
Sponsor: Pfizer
Recruiting - verified March 2010
An Observational Study of Fungal Biomarkers

Condition: Aspergillosis
Intervention: Other: No Intervention
Sponsor: Merck
Recruiting - verified March 2010
A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

Condition: Hypertension, Pulmonary
Interventions: Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: placebo; Drug: sildenafil
Sponsor: Pfizer
Recruiting - verified February 2010
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)

Condition: Non-small Cell Lung Cancer
Interventions: Drug: erlotinib HCl; Drug: MetMAb; Drug: placebo
Sponsor: Genentech
Recruiting - verified March 2010
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

Conditions: Impetigo; Secondarily-infected Traumatic Lesions
Interventions: Drug: Linezolid; Drug: Retpamulin Ointment, 1%
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

Condition: Advanced Renal Cell Carcinoma
Interventions: Drug: AMG386; Drug: Sunitinib
Sponsor: Amgen
Recruiting - verified February 2010
Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression

Condition: Bipolar Depression
Interventions: Drug: cariprazine; Drug: cariprazine; Drug: placebo
Sponsors: Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2010
Study of Stem Cell Transplant for Leukemia and Myelodysplatic Syndroms Using Clofarabine and Busulfan Regimen

Conditions: Leukemia; Myelodysplastic Syndrome
Intervention: Drug: Clofarabine/Busulfan
Sponsors: Baylor Research Institute; Genzyme
Recruiting - verified February 2010
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: fluoxetine; Drug: duloxetine; Drug: duloxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

Condition: Colorectal Cancer (CRC)
Interventions: Drug: Irinotecan; Drug: 5-Fluorouracil (bolus); Drug: 5-Fluorouracil (infusional); Drug: Leucovorin calcium; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab Placebo (saline solution)
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: duloxetine; Drug: Placebo; Drug: fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Conditions: B-Cell Lymphoma; B-Cell Leukemia
Intervention: Drug: PCI-32765
Sponsor: Pharmacyclics
Recruiting - verified July 2009
A Phase I Study of MK2206 in Combination With Standard Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors

Condition: Locally Advanced, Metastatic Solid Tumors
Interventions: Drug: MK2206 combined with carboplatin + paclitaxel; Drug: MK2206 combined with docetaxel.; Drug: MK2206 combined with Erlotinib
Sponsor: Merck
Recruiting - verified March 2010
Efficacy and Safety of TAK-491 Combined With Chlorthalidone in Subjects With Moderate to Severe Hypertension

Condition: Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Chlorthalidone; Drug: Chlorthalidone; Drug: TAK-491; Drug: TAK-491; Drug: TAK-491
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis

Condition: Psoriasis
Interventions: Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 subcutaneous injection
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Flexitouch Treatment for Venous Ulcers

Condition: Venous Ulcer
Interventions: Device: Standard Wound Care; Device: Flexitouch System with Standard Wound Care
Sponsor: Tactile Systems Technology Inc.
Recruiting - verified March 2010
Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis

Conditions: Gastroparesis; Diabetic Gastroparesis; Diabetes; Diabetes Mellitus; Delayed Gastric Emptying
Interventions: Drug: metoclopramide; Drug: Placebo
Sponsor: Evoke Pharma
Recruiting - verified March 2010
A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation

Conditions: Lung Cancer; Head and Neck Cancer
Intervention: Drug: [F-18]FLT
Sponsor: Siemens Molecular Imaging
Recruiting - verified March 2010
Open-Label Study of Oral Treprostinil in Digital Ulcers

Condition: Systemic Sclerosis
Intervention: Drug: treprostinil diethanolamine
Sponsor: United Therapeutics
Not yet recruiting - verified February 2009
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse

Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
Efficacy and Safety of Azilsartan Plus Chlorthalidone in Subjects With Moderate to Severe Hypertension

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression

Condition: Bipolar Depression
Interventions: Drug: Olanzapine Fluoxetine Combination; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
A Trial of Patients With Metastatic Adenocarcinoma of the Pancreas

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified December 2009
Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

Condition: Acute Decompensated Heart Failure
Intervention: Drug: CD-NP
Sponsor: Nile Therapeutics
Recruiting - verified March 2010
A Study for Patients With Pancreatic Cancer

Condition: Pancreatic Neoplasms
Interventions: Drug: LY2603618; Drug: Gemcitabine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer

Conditions: Cancer; Carcinoma; Castrate-Resistant Prostate Cancer; Prostate Cancer; Tumors
Intervention: Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Breast Cancers: Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.

Condition: Breast Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Effects of Weight Loss From Bariatric Surgery on IOP

Condition: Intraocular Pressure
Intervention:
Sponsor: The University of Texas Health Science Center, Houston
Not yet recruiting - verified February 2010
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

Condition: Invasive Aspergillosis
Intervention: Drug: Voriconazole
Sponsor: Pfizer
Recruiting - verified February 2010
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Condition: Carcinoma, Renal Cell
Interventions: Drug: axitinib; Drug: axitinib; Drug: axitinib
Sponsor: Pfizer
Recruiting - verified March 2010
A Safety Study of VIVITROL® Administered to Health Care Professionals

Condition: Opioid Dependency
Intervention: Drug: VIVITROL
Sponsor: Alkermes
Recruiting - verified February 2010
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects

Conditions: Metastatic; Colorectal Cancer
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin); Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Sponsors: Bayer; Onyx Pharmaceuticals
Recruiting - verified February 2010
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase III Acute Coronary Syndrome

Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
An Observational Study of Cholesterol in Coronary Arteries

Conditions: Myocardial Infarction; Angina; Coronary Artery Disease; Myocardial Ischemia
Intervention: Device: Intravascular Near Infrared Spectroscopy
Sponsor: InfraReDx
Recruiting - verified February 2010
Effects of Carotid Stent Design on Cerebral Embolization

Conditions: Stroke; Carotid Stenosis
Interventions: Device: closed-cell stent; Device: Open-cell stent
Sponsor: Dallas VA Medical Center
Recruiting - verified February 2010
Tanezumab In Osteoarthritis Of The Knee (2)

Conditions: Arthritis; Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Cetuximab; Drug: Paclitaxel; Drug: Carboplatin; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: Accelerated Community Oncology Research Network; ImClone LLC; Advanced Clinical Trial Solutions, LLC
Recruiting - verified February 2010
Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials

Condition: Solid Tumors
Intervention: Drug: AG-013736
Sponsor: Pfizer
Recruiting - verified March 2010
Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: aflibercept; Drug: topotecan hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study Comparing Two Methods of Expanding Stents Placed in Legs of Diabetics With Peripheral Vascular Disease

Condition: Peripheral Vascular Disease
Interventions: Procedure: Conventional angioplasty balloon; Procedure: cryoplasty balloon
Sponsors: Boston Scientific Corporation; Texas Health Resources
Recruiting - verified January 2010
A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Condition: Human Immunodeficiency Virus-1
Interventions: Drug: maraviroc; Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Uterine Artery Embolization and Pelvic Floor Symptoms

Conditions: Leiomyoma; Incontinence; Prolapse
Intervention:
Sponsor: University of Texas Southwestern Medical Center
Recruiting - verified January 2010
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Condition: Liver Cancer
Interventions: Drug: Brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

Condition: Multiple Sclerosis
Intervention: Other: Single-Use Autoinjector with a Pre-Filled Liquid Avonex Syringe
Sponsor: Biogen Idec
Recruiting - verified February 2010
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 or Lapatinib or Trastuzumab

Condition: Breast Neoplasms
Interventions: Drug: trastuzumab; Drug: lapatinib; Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

Condition: HIV-1
Interventions: Drug: UK-453,061 Dose 1; Drug: UK-453,061 Dose 2; Drug: Etravirine
Sponsor: Pfizer
Recruiting - verified February 2010
A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Understanding Patient's Knowledge and Use of Acetaminophen

Condition: Liver Failure
Interventions: Behavioral: Focus Groups; Behavioral: Personal Interviews
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1

Condition: HIV-1
Interventions: Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed
Sponsor: Pfizer
Recruiting - verified February 2010
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Hedgehog antagonist GDC-0449; Genetic: gene expression analysis; Genetic: in situ hybridization; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified January 2010
Study of MK0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain

Condition: Postorthopedic Knee Replacement Surgery Pain
Interventions: Drug: etoricoxib; Drug: Comparator: ibuprofen; Drug: Comparator: placebo
Sponsor: Merck
Recruiting - verified March 2010
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease

Condition: Alzheimer´s Disease
Interventions: Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%); Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%); Other: Placebo solution
Sponsors: Baxter Healthcare Corporation; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified March 2010
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.

Condition: Breast Cancer
Intervention: Device: Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
Sponsor: U-Systems, Inc.
Recruiting - verified February 2010
Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone Immediate Release (IR) for Treatment of Acute Post-op Pain Following Elective Arthroscopic Shoulder Surgery

Condition: Postoperative Pain
Interventions: Drug: Oxycodone IR; Drug: Tapentadol IR
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal GmbH
Recruiting - verified February 2010
Phase 2 Safety & Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 vs FOLFIRI in KRAS-mutant Metastatic Colorectal Carcinoma

Condition: Metastatic Colorectal Cancer
Interventions: Biological: AMG 479; Other: Placebo; Other: FOLFIRI; Biological: AMG 655
Sponsor: Amgen
Recruiting - verified March 2010
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib

Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsor: Bayer
Recruiting - verified March 2010
Comparative Study of Three NNRTI-Sparing HAART Regimens

Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Raltegravir; Drug: Darunavir; Drug: Ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Bristol-Myers Squibb; Gilead Sciences; Merck; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Recruiting - verified June 2009
Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis

Conditions: Lupus; Nephritis; Systemic Lupus Erythematosus
Intervention: Drug: AMG 811
Sponsor: Amgen
Recruiting - verified February 2010
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

Condition: Waldenstrom's Macroglobulinemia
Intervention: Biological: Ofatumumab
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome.

Conditions: Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Unstable Angina
Intervention: Drug: Rivaroxaban; Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Bayer
Recruiting - verified February 2010
Extension Study Of Tanezumab In Osteoarthritis

Condition: Osteoarthritis
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab
Sponsor: Pfizer
Recruiting - verified March 2010
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

Conditions: Osteoarthritis; Arthritis
Interventions: Drug: NSAID; Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Drug: NSAID; Biological: tanezumab; Drug: NSAID
Sponsor: Pfizer
Recruiting - verified February 2010
A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: methotrexate; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

Condition: Asthma
Interventions: Drug: Levalbuterol; Drug: Levalbuterol UDV TID; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

Condition: Rheumatoid Arthritis
Interventions: Drug: infliximab; Drug: methotrexate; Drug: methylprednisolone; Drug: ocrelizumab; Drug: sham
Sponsor: Genentech
Recruiting - verified February 2010
A Phase 4, 6-Week, Randomized Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

Condition: Arthritis, Juvenile Rheumatoid
Interventions: Drug: Celecoxib; Drug: Naproxen
Sponsor: Pfizer
Recruiting - verified March 2010
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: Folic Acid; Drug: BIBF1120 placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

Condition: Idiopathic Restless Legs Syndrome
Interventions: Drug: placebo and pregabalin; Drug: pramipexol; Drug: pramipexol; Drug: Pregabalin; Drug: pramipexol; Drug: pramipexol
Sponsor: Pfizer
Recruiting - verified March 2010
Study of NNZ-2566 in Patients With Traumatic Brain Injury

Condition: Brain Injuries
Intervention: Drug: NNZ-2566
Sponsor: Neuren Pharmaceuticals Limited
Not yet recruiting - verified March 2010
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Ataluren (PTC124™) in Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124); Drug: Placebo
Sponsors: PTC Therapeutics; Genzyme; Cystic Fibrosis Foundation
Recruiting - verified March 2010
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Conditions: Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease; CV Risk
Interventions: Drug: Darapladib; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299, GSK Biological's HPV vaccine
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Targeting Inflammation Using Salsalate for Type 2 Diabetes-stage II

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Salsalate; Drug: Salsalate Placebo
Sponsors: Joslin Diabetes Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Rollover Protocol for Prior SU011248 Protocols

Condition: Solid Tumors
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor.

Condition: Resected Stage III Melanoma With Macroscopic Involvement
Interventions: Drug: GSK 2132231A; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: RG1507; Drug: letrozole
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
SR-PAAS - Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

Conditions: PAH; Pulmonary Arterial Hypertension; Pulmonary Hypertension; Sitaxsentan; ETRA
Interventions: Drug: Sitaxsentan; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; ETRA; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Recruiting - verified March 2010
Open-label Study Providing Monotherapy (Sitaxsentan) and Combination Therapy (Sitaxsentan+Sildenafil) to Subjects With PAH to Assess Long-term Safety

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Not yet recruiting - verified March 2010
A Study of the Safety and Effectiveness of Trabetedin Versus Doxorubicin-based Chemotherapy in Patients With Translocation-Related Sarcomas (TRS)

Conditions: Soft Tissue Sarcomas; Translocation-Related Sarcomas (TRS)
Intervention: Drug: Trabectedin, ET 743 and Yondelis
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar
Recruiting - verified February 2010
Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients

Condition: Breast Cancer
Interventions: Procedure: Echocardiograms; Procedure: Blood Test
Sponsors: M.D. Anderson Cancer Center; Massachusetts General Hospital
Recruiting - verified March 2010
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery

Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Other: active surveillance
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Moderate to Severe Plaque Psoriasis With Scalp Involvement

Condition: Psoriasis
Interventions: Drug: etanercept / placebo; Drug: placebo / etanercept
Sponsor: Amgen
Recruiting - verified February 2010
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Maraviroc
Sponsor: Pfizer
Recruiting - verified February 2010
Efficacy and Safety of RAD001 in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)

Condition: Tuberous Sclerosis
Interventions: Drug: RAD001 (Everolimus); Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Sitagliptin Cardiovascular Outcome Study

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Comparator: Placebo
Sponsors: Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified February 2010
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

Condition: Chronic Schizophrenia
Interventions: Drug: Lurasidone HCl; Drug: quetiapine XR
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

Condition: Schizophrenia
Interventions: Drug: Lurasidone HCl; Drug: Lurasidone HCl; Drug: quetiapine XR; Drug: Placebo
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Phase II Study of TKI258 in Advanced Urothelial Carcinoma

Condition: Urothelial Cancer
Intervention: Drug: TKI258
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
PEAK: A Phase 2 Study of Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer Subjects With Wild-Type KRAS Tumors

Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsor: Amgen
Recruiting - verified March 2010
A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain

Condition: Acute Pain Following a Total Abdominal Hysterectomy
Interventions: Drug: etoricoxib (MK0663); Drug: Comparator: Placebo
Sponsor: Merck
Recruiting - verified March 2010
Phase III, Open-label Study of Nilotinib Versus Imatinib in GIST Patients

Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
An Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233AM1)

Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Conditions: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
Interventions: Drug: maraviroc; Drug: etravirine
Sponsor: Pfizer
Recruiting - verified March 2010
Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

Conditions: Hematologic Disease; Blood Coagulation Disorders
Interventions: Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222); Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222); Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222)
Sponsor: Bayer
Recruiting - verified March 2010
Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)

Condition: Myocardial Infarction
Intervention: Drug: Clopidogrel
Sponsor: Dallas VA Medical Center
Recruiting - verified January 2009
Multicenter Study of IMC-A12 in Combination With Depot Octreotide in Patients With Carcinoid or Islet Cell Cancer

Conditions: Carcinoma; Neuroendocrine Tumors
Intervention: Biological: A12
Sponsor: ImClone LLC
Recruiting - verified February 2010
Panitumumab Combination Study With AMG 102 or AMG 479 in Wild-type KRAS mCRC

Conditions: Colon Cancer; Colorectal Cancer; Gastrointestinal Cancer; Metastatic Colorectal Cancer; Rectal Cancer
Interventions: Drug: Panitumumab + AMG 102; Drug: Panitumumab + AMG 479; Drug: AMG 479; Drug: AMG 102; Drug: Panitumumab
Sponsor: Amgen
Recruiting - verified March 2010
A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

Conditions: Lung Cancer; Small Cell Lung Cancer; Solid Tumors; Extensive-Stage Small Cell Lung Cancer
Interventions: Drug: AMG 102 in combination with Cisplatin/Etopiside; Drug: AMG 479 in combination with Carboplatin/Etopiside; Drug: AMG 102 in combination with Carboplatin/Etopiside; Drug: AMG 479 in combination with Cisplatin/Etopiside
Sponsor: Amgen
Recruiting - verified March 2010
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.

Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
PKUDOS: PKU Demographic, Outcomes, and Safety Registry

Conditions: Phenylketonuria; Hyperphenylalaninaemia
Intervention: Drug: Sapropterin Dihydrochloride
Sponsor: BioMarin Pharmaceutical
Recruiting - verified January 2010
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

Conditions: Systemic Sclerosis; Scleroderma
Interventions: Drug: treprostinil diethanolamine; Drug: placebo
Sponsor: United Therapeutics
Recruiting - verified February 2010
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

Conditions: Lupus Nephritis; Lupus Erythematosus, Systemic
Interventions: Drug: Abatacept; Drug: cyclophosphamide; Drug: azathioprine; Drug: prednisone; Drug: abatacept placebo; Drug: azathioprine placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network
Recruiting - verified February 2010
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); Bacchus Vascular; BSN Medical Inc; Genentech; MEDRAD Interventional/Possis; Mid America Heart Institute; Society of Interventional Radiology Foundation; VasCore at Massachusetts General Hospital
Recruiting - verified February 2010
NINDS CRC Chronic Migraine Treatment Trial

Condition: Chronic Migraine
Interventions: Drug: propranolol LA; Drug: topiramate; Drug: placebo
Sponsors: The EMMES Corporation; National Institute of Neurological Disorders and Stroke (NINDS); Ortho-McNeil Janssen Scientific Affairs, LLC; CRC Operations Center
Recruiting - verified March 2010
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: vorinostat (an HDAC inhibitor); Drug: bortezomib
Sponsor: Merck
Recruiting - verified February 2010
A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU

Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsor: USHIFU, LLC
Recruiting - verified March 2010
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care

Condition: Asthma
Interventions: Drug: tiotropium 5mcg/day; Drug: tiotropium 5mcg/day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohns Disease Who Have Been Previously Treated With Anti-TNF Therapy

Condition: Crohn's Disease
Intervention: Drug: Ustekinumab; CNTO1275
Sponsor: Centocor, Inc.
Recruiting - verified March 2010
Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

Condition: Back Pain
Interventions: Drug: placebo; Drug: tapentadol IR; Drug: oxycodone IR
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal GmbH
Not yet recruiting - verified February 2010
An Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234AM2)

Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 1.5 Amb a 1-U; Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer

Condition: Prostate Cancer
Interventions: Device: HIFU (Sonablate® 500); Device: Brachytherapy
Sponsor: USHIFU, LLC
Recruiting - verified March 2010
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma

Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified March 2010
(ARTEMIS-IPF)Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified March 2010
CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

Condition: Glioblastoma Multiforme
Interventions: Drug: CT-322; Drug: Temozolomide; Procedure: Radiation Therapy
Sponsor: Adnexus, A Bristol-Myers Squibb R&D Company
Recruiting - verified March 2010
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

Condition: Diabetic Macular Edema
Interventions: Drug: Aliskiren; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Viral Shedding of MEDI-559 in Healthy 1 to <24 Month-Old Children

Condition: Healthy
Interventions: Biological: MEDI-559; Other: Placebo; Biological: MEDI-559
Sponsor: MedImmune LLC
Recruiting - verified March 2010
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Condition: Non-small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: Placebo; Drug: RG1507; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Study To Assess The Safety, Pharmacokinetics, And Evaluate The Response To Anidulafungin When Treating Children With Invasive Candidiasis

Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsor: Pfizer
Recruiting - verified March 2010
Expanded Access of Prochymal Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Conditions: Graft vs Host Disease; Graft-Versus-Host Disease
Intervention: Drug: Prochymal®
Sponsors: Osiris Therapeutics; Quintiles
Available - verified February 2010
Safety and Efficacy Study of Saxagliptin Added to Insulin Alone or to Insulin Taken With Metformin

Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Placebo
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified October 2009
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Condition: Optic Neuropathy, Ischemic
Intervention:
Sponsor: Pfizer
Recruiting - verified March 2010
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Drug: docetaxel; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Prostate Active Surveillance Study

Condition: Prostatic Neoplasms
Intervention:
Sponsors: University of Washington; Canary Foundation; Early Detection Research Network
Recruiting - verified February 2010
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN®; Drug: Carboplatin; Drug: Paclitaxel
Sponsor: Oncolytics Biotech
Recruiting - verified March 2010
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: rhGAD65; Drug: rhGAD65; Drug: Placebo
Sponsor: Diamyd Therapeutics AB
Recruiting - verified March 2010
A Placebo-Controlled Study of AZD0530 in Patients With Recurrent Osteosarcoma Localized to the Lung

Condition: Osteosarcoma
Interventions: Drug: AZD0530; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration; AstraZeneca
Recruiting - verified February 2010
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase II Trial of BIBW 2992 in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Condition: Neoplasms
Intervention: Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Ofatumumab + Chlorambucil vs. Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ofatumumab (GSK1841157) infusion; Drug: chlorambucil, tablets
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Pharmacokinetic, Pharmacodynamic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Condition: GERD
Intervention: Drug: Rabeprazole sodium
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified February 2010
Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer

Condition: Rectal Cancer
Interventions: Drug: Curcumin; Drug: Placebo; Radiation: Radiotherapy; Drug: Capecitabine
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: taspoglutide; Drug: placebo; Drug: pioglitazone; Drug: metformin
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Tanezumab in Osteoarthritis Of The Hip

Conditions: Arthritis; Osteoarthritis; Osteoarthritis, Hip
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Biological: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010

Find Paid Clinical Trials in Abbott, Texas - Clinical Trials

Find Paid Clinical Trials in Abbott, Texas

Paid Clinical Trials and Focus Groups by Location